NCT02287558View on ClinicalTrials.gov

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 27, 2015

Primary Completion Date

June 1, 2019

Study Completion Date

June 1, 2019

Conditions
Hereditary Hemorrhagic TelangiectasiaIdiopathic Vascular Ectasia
Interventions
DRUG

Pomalidomide

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
lead

The Cleveland Clinic

OTHER

NCT02287558 - Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study | Biotech Hunter | Biotech Hunter